203 related articles for article (PubMed ID: 26749403)
1. Anakinra-Induced Acute Liver Failure in an Adolescent Patient with Still's Disease.
Taylor SA; Vittorio JM; Martinez M; Fester KA; Lagana SM; Lobritto SJ; Ovchinsky N
Pharmacotherapy; 2016 Jan; 36(1):e1-4. PubMed ID: 26749403
[TBL] [Abstract][Full Text] [Related]
2. Anakinra in children and adults with Still's disease.
Vastert SJ; Jamilloux Y; Quartier P; Ohlman S; Osterling Koskinen L; Kullenberg T; Franck-Larsson K; Fautrel B; de Benedetti F
Rheumatology (Oxford); 2019 Nov; 58(Suppl 6):vi9-vi22. PubMed ID: 31769856
[TBL] [Abstract][Full Text] [Related]
3. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Kalliolias GD; Liossis SN
Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
[TBL] [Abstract][Full Text] [Related]
4. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
6. [Anakinra in refractory adult onset Still's disease].
Vercoutere W; Starmans-Kool M; Peeters RM
Ned Tijdschr Geneeskd; 2011; 155(18):A2966. PubMed ID: 21466723
[TBL] [Abstract][Full Text] [Related]
7. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report.
Guignard S; Dien G; Dougados M
Clin Exp Rheumatol; 2007; 25(5):758-9. PubMed ID: 18078628
[TBL] [Abstract][Full Text] [Related]
8. [Severe hepatitis in a patient with adult-onset Still's disease treated with anakinra].
Diallo A; Mekinian A; Boukari L; Mouas H; Zamy M; Nahon P; Gérin M; Fain O
Rev Med Interne; 2013 Mar; 34(3):168-70. PubMed ID: 23182291
[TBL] [Abstract][Full Text] [Related]
9. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
[TBL] [Abstract][Full Text] [Related]
10. Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
Hoffmann MC; Cavalli G; Fadle N; Cantoni E; Regitz E; Fleser O; Klemm P; Zaks M; Stöger E; Campochiaro C; Tomelleri A; Baldissera E; Bittenbring JT; Zimmer V; Pfeifer J; Fischer Y; Preuss KD; Bewarder M; Thurner B; Fuehner S; Foell D; Dagna L; Kessel C; Thurner L
J Clin Immunol; 2024 Jan; 44(2):45. PubMed ID: 38231276
[TBL] [Abstract][Full Text] [Related]
11. A case of bilateral trochleitis in adult-onset Still's disease.
Gutmark R; Eliasieh K; Rivera-Michlig R
Semin Arthritis Rheum; 2014 Apr; 43(5):689-91. PubMed ID: 24176730
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.
Nordström D; Knight A; Luukkainen R; van Vollenhoven R; Rantalaiho V; Kajalainen A; Brun JG; Proven A; Ljung L; Kautiainen H; Pettersson T
J Rheumatol; 2012 Oct; 39(10):2008-11. PubMed ID: 22859346
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study.
Laskari K; Tzioufas AG; Moutsopoulos HM
Arthritis Res Ther; 2011 Jun; 13(3):R91. PubMed ID: 21682863
[TBL] [Abstract][Full Text] [Related]
14. Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still's disease.
Tamaki H; Shimizu H; Hiraoka E; Uechi E; Kishimoto M; Yamaguchi K; Okada M
Mod Rheumatol; 2010 Apr; 20(2):200-4. PubMed ID: 20037747
[TBL] [Abstract][Full Text] [Related]
15. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
16. The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature.
Giacomelli R; Sota J; Ruscitti P; Campochiaro C; Colafrancesco S; Dagna L; Iacono D; Iannone F; Lopalco G; Sfriso P; Cantarini L
Clin Exp Rheumatol; 2021; 39(1):187-195. PubMed ID: 32452353
[TBL] [Abstract][Full Text] [Related]
17. Is IL-1 a good therapeutic target in the treatment of arthritis?
Burger D; Dayer JM; Palmer G; Gabay C
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):879-96. PubMed ID: 16980212
[TBL] [Abstract][Full Text] [Related]
18. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.
Giampietro C; Ridene M; Lequerre T; Costedoat Chalumeau N; Amoura Z; Sellam J; Sibilia J; Bourgeois P; Fautrel B;
Arthritis Care Res (Hoboken); 2013 May; 65(5):822-6. PubMed ID: 23225779
[TBL] [Abstract][Full Text] [Related]
19. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).
Hedrich CM; Bruck N; Fiebig B; Gahr M
Rheumatol Int; 2012 Nov; 32(11):3525-30. PubMed ID: 22083619
[TBL] [Abstract][Full Text] [Related]
20. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]